Hemispherx BioPharma (HEB)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You
TheStreet.com  Feb 4  Comment 
PHILADELPHIA, Pa. (TheStreet) -- A medical-research branch of the U.S. Army is denying claims made by Hemispherx BioPharma touting a research collaboration to study two of the company's drugs against the Ebola virus. In September, Hemispherx...
Health Exchange: Tiny biotech says it may have an answer for Ebola
MarketWatch  Feb 2  Comment 
A tiny biotechnology company, Hemispherx Biopharma Inc., says it may have a foolproof solution for the Ebola virus.
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
Benzinga  Dec 16  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod) as a potential therapeutic complement to a new molecular class of anti-tumor drugs termed immune...
Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx
TheStreet.com  Oct 31  Comment 
BOSTON (TheStreet) --aWelcome back to this week's Biotech Stock Mailbag. @adamfeuerstein any thoughts on rna after the debacle with srpt? — Joe Smith (@zwerp2000) October 27, 2014 I'm assuming Prosensa completes the submission of...
Hemispherx Biopharma (HEB) Reports Evidence Based Potential of Ampligen Against Ebola
StreetInsider.com  Oct 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Reports+Evidence+Based+Potential+of+Ampligen+Against+Ebola+/9957255.html for the full story.
Hemispherx Joins The Ebola Game
Benzinga  Oct 22  Comment 
This was a recent headline from earlier this week: "Hemispherx Announces Strategic Relationship with Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola" While a lot of attention has been paid to names such as...
Hemispherx Biopharma (HEB) to Lobby For Additional Pathways For Testing Ampligen
StreetInsider.com  Oct 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+to+Lobby+For+Additional+Pathways+For+Testing+Ampligen/9926067.html for the full story.
Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental Counsel In Fight Against Ebola
Benzinga  Oct 20  Comment 
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government relations team in an effort to help find additional pathways for testing Hemispherx's flagship...




more ▼WIKI ANALYSIS
Error creating thumbnail
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Hemispherx BioPharma (HEB):

 
TOP CONTRIBUTORS
Associate
James W Miller
 Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.



References

http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Retrieved from "http://bot.wikinvest.com/stock/Hemispherx_BioPharma_(HEB)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki